Amarillo Biosciences Appoints Bernard Cohen CFO
Previously, Mr. Cohen was Director of Finance and Data Base Manager at Harrington Regional Medical Center in
“I am extremely pleased to be joining Amarillo Biosciences at a time in which the company has a potential solution to the swine flu pandemic,” said
About Amarillo Biosciences --------------------------
Amarillo Biosciences, Inc. is a U.S. biotechnology firm operating in global partnership with the Hayashibara Group, which also holds 7% of Amarillo Biosciences shares and has provided over
Except for the historical information contained herein, the matters discussed in this news release are forward-looking statements that involve risks and uncertainties, including uncertainties related to product development, uncertainties related to the need for regulatory and other government approvals, dependence on proprietary technology, uncertainty of market acceptance of oral interferon or the Company’s other product candidates and other risks detailed from time to time in the Company’s filings with the Securities and Exchange Commission. In particular, see “Item 1. Description of Business” and “Item 7A. Qualitative and Quantitative Disclosures About Market Risk” of the Company’s Form 10-K for the fiscal year ended
SOURCE Amarillo Biosciences, Inc.